News | Vascular Access | March 31, 2017

FDA Recalls Merit Medical Systems' Prelude Short Sheath Introducer

Class I recall initiated over reports that sheath may separate during use, which agency says may cause serious injury or death.

Merit Medical, FDA Class I recall, Prelude Short Sheath Introducer

March 31, 2017 — The U.S. Food and Drug Administration (FDA) announced it has initiated a Class I recall of the Merit Prelude Short Sheath Introducer, warning that a manufacturing defect may cause the tip to separate from the sheath during the separation procedure. The agency said that if this occurs, the tip could enter the patient’s bloodstream. This may result in prolonged procedure times, additional surgery to remove the tip from the patient, blood clots, internal tears and perforation to arteries or veins, excessive bleeding and death.

The Merit Prelude Short Sheath Introducer is used to guide the placement of catheters, grafts, and other medical devices into the veins and arteries. The device is also used during temporary hemodialysis, a treatment for kidney failure.

Lot numbers affected by the recall include H1041469, H1041473, H1036880 and H1041464; catalog numbers include K15-00070, K15-00170, PSS-7F-4-035MT and PSS-7F-4MT. The recall impacts products manufactured from Nov. 23-30, 2016, and distributed between Dec. 15, 2016 and Jan. 18, 2017. The FDA said a total of 1,265 units are impacted by the recall.

Merit Medical sent an Urgent Product Recall Notice to affected customers on Feb. 16, 2017, asking them to:

  • Ensure appropriate staff is aware of the notice;
  • Quarantine any affected products and discontinue use;
  • Complete the Customer Response Form attached to the notice and return by email at [email protected]; and
  • Return all affected lots in possession to Merit Medical Inc. per the instructions found in the Customer Response Form.

Customers are instructed to contact their Merit Sales Representative or Merit Customer Service by telephone at 801.208.4381 with any questions related to this recall.

Healthcare professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program either online, by regular mail or by fax to 1-800-FDA-0178.

For more information:;

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init